Luke Funk, MD, MPH, FACS


  • Chief of General Surgery, William S. Middleton VA 
  • Vice Chair of Research
  • Division of Minimally Invasive Surgery

Dr. Luke Funk’s CV
(608) 263-1036

  • Administrative Assistant: (608) 263-1036

600 Highland Ave
MC 7375
Madison, WI 53792-0001


  • MD, Loyola University Chicago Stritch School of Medicine, Maywood, IL
  • MPH, Harvard School of Public Health, Boston, MA
  • General Surgery Residency, Brigham and Women's Hospital, Boston, MA
  • Fellowship in Minimally Invasive Surgery, The Ohio State University Wexner Medical Center, Columbus, OH

Clinical Specialties

Dr. Funk is fellowship trained in Minimally Invasive Surgery and Bariatric Surgery and is board certified in General Surgery. He is a member of the Society of American Gastrointestinal and Endoscopic Surgeons, the American Society of Metabolic and Bariatric Surgeons, and the American College of Surgeons. He specializes in minimally invasive techniques for bariatric and metabolic surgery, esophageal and gastric disorders, abdominal wall hernias, and gall bladder disorders.

Research Interests

Nearly 80% of U.S. adults meet criteria for overweight/obesity. All three evidence-based obesity treatment options – behavioral weight management, obesity medications and bariatric surgery – are significantly underutilized. As a surgeon scientist, my long-term goal is to optimize access and outcomes of obesity care for adults with overweight/obesity. Our group uses quantitative (e.g., database analysis) and qualitative research methods (e.g., interviews and focus groups) and conducts clinical trials aimed at improving outcomes for adults with obesity. We are also focused on addressing socioeconomic disparities pertaining to obesity treatment and are currently conducting a mixed-methods analysis of patients who have undergone bariatric surgery in an effort to understand barriers to optimal outcomes. Our research group is located at both the University of Wisconsin-Madison and William S. Middleton Veterans Memorial Hospital.

Recent Publications

  • Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
    Samuels JM, Niswender KD, Roumie CL, Spann MD, Flynn CR, Ye F, Blankush J, Irlmeier R, Funk LM, Patel MB
    Diabetes Obes Metab 2024 Jun 27;
    [PubMed ID: 38934217]

  • The TOTAL trial for weight management participation: A randomized controlled trial protocol.
    Funk LM, Williams CB, Breuer CR, Hetzel S, LaSage SC, Villasenor CJ, Moin T, Cook J, Sampene E, Stroupe KT, Alagoz E, Raffa SD, Voils CI
    Contemp Clin Trials 2024 Jun 22; 144: 107611
    [PubMed ID: 38914310]

  • Exploring Social Support Dynamics After Bariatric Surgery: Insights From Patients and Providers.
    Jawara D, Alagoz E, Lauer KV, Voils CI, Funk LM
    J Surg Res 2024 Jul; 299: 1-8
    [PubMed ID: 38677002]

  • Metabolic Surgery for Diabetes Management.
    Kindel TL, Funk LM, Ghaferi AA
    JAMA Surg 2024 Jun 01; 159(6): 602-603
    [PubMed ID: 38568511]

  • Moving from scores to solutions: Lessons learned from the social vulnerability index and disparities in surgical outcomes.
    Jawara D, Funk LM
    Am J Surg 2024 Mar; 229: 24-25
    [PubMed ID: 38008649]

All Publications on PubMed